Q
Quentis Therapeutics
Quentis Therapeutics a biotechnology company
About Quentis Therapeutics
Quentis Therapeutics, founded in 2016 by Juan Cubillos-Ruiz and Sarah Bettigole, was a biotechnology company focused on developing therapies for cancer and neurodegenerative diseases. The company's scientific basis stemmed from research at Weill Cornell Medicine by Laurie Glimcher, M.D., and co-founder Juan Cubillos-Ruiz, Ph.D., which identified the crucial role of the endoplasmic reticulum (ER) stress response in compromising the immune system's ability to combat cancer. This research indicated that chronic activation of ER stress is linked to poor outcomes in various cancers, including ovarian, triple-negative breast, pancreatic, and glioblastoma.
The company's primary business was the research and development of cancer immunotherapies designed to modulate these ER stress response pathways within the tumor microenvironment. By doing so, Quentis aimed to enhance a patient's own anti-tumor immunity. The business model was centered on advancing its therapeutic candidates through preclinical and clinical trials to eventually secure regulatory approval and commercialize them. The company's lead product candidate was a first-in-class small molecule inhibitor of the inositol-requiring enzyme 1 α (IRE1α). This enzyme is a central component in the ER stress-response signaling pathway, and inhibiting it was intended to reduce ER stress and boost anti-tumor immunity.
Quentis secured significant funding to advance its pipeline, raising a total of $51 million over three rounds. This included a $48 million Series A financing in February 2018, co-led by Versant Ventures and Polaris Partners, with participation from AbbVie Ventures, Taiho Pharmaceutical, and others. These funds were allocated to advance the lead IRE1α inhibitor program into the clinic in 2019, develop a pipeline of preclinical programs, and expand the team. Despite its promising start and being named one of Fierce Biotech's "Fierce 15" of 2018, Quentis Therapeutics is no longer active and is considered a deadpooled company as of March 2022.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| GRANTOther financing | Dec 2018 | $1M | — | Undisclosed | — |
| SERIES AOther financing | Feb 2018 | $48M | $192M | Abbvie Biotech Ventures · Polaris Partners · Alexandria Venture Investments · Yonghua Capital | — |
Growth signals
Latest recorded traffic for Quentis Therapeutics is 80 monthly website visits, down 83.3% over the last three months.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Quentis Therapeutics in the New York City ecosystem
The Quentis Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A5 investors entered at this stage
Polaris Partners
Versant Ventures
Abbvie Biotech Ventures
Alexandria Venture Investments
Yonghua Capital
Other known investors1 additional known investor
MD Anderson Cancer Center
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Quentis Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Quentis Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









